Gilead SciencesFRA:GIS -0.79%75 OCF Margin % is 36.55% as of Mar. 2026, which is 3% below its 10-year median of 37.81. GuruFocus rates FRA:GIS with a GF Score™ of 75/100 and a GF Value™ of €81.25 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Gilead Sciences ranks better than 96.14% on this metric.
The historical rank and industry rank for Gilead Sciences's OCF Margin % or its related term are showing as below:
FRA:GIS'
s OCF Margin % Range Over the Past 10 Years
Min: 29.53 Med: 37.81 Max: 56.09
Current: 36.24
During the past 13 years, the highest OCF Margin % of Gilead Sciences was 56.09%. The lowest was 29.53%. And the median was 37.81%.
FRA:GIS's OCF Margin % is ranked better than 96.14% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs FRA:GIS: 36.24
Gilead Sciences OCF Margin % Related Terms
Gilead Sciences OCF Margin % Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GIS vs AMGN, PFE, BMY: OCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (FRA:GIS) has a OCF Margin % of 36.55% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Gilead Sciences and its competitors. This is near median its historical median of 37.81. Over the past decade, Gilead Sciences' OCF Margin % has ranged from 29.53 to 56.09. According to the industry distribution chart, Gilead Sciences ranks #37 out of 959 companies in the Drug Manufacturers industry, placing it in the top 3.9%.
Is Gilead Sciences' OCF Margin % too high?
Gilead Sciences' current OCF Margin % of 36.55% is near median its 10-year median of 37.81. Over the past 10 years, this metric has ranged from a low of 29.53 to a high of 56.09. The Drug Manufacturers industry median OCF Margin % is 9.94. Gilead Sciences' value of 36.55% is 267.7% above this industry median. Based on the distribution chart, Gilead Sciences ranks #37 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' OCF Margin % compare to AMGN and PFE?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #37 out of 959 companies for OCF Margin %. This places Gilead Sciences in the top 4% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.94. Gilead Sciences' value of 36.55% is 267.7% above this benchmark. Historically, Gilead Sciences' own OCF Margin % has ranged from 29.53 to 56.09 over the past decade. While the company's 10-year median is 37.81 vs. the industry median of 9.94, Gilead Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current OCF Margin % of 36.55% is 267.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current OCF Margin % is 36.55%, which is near median its own 10-year median of 37.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €81.25, compared to a current price of €108.26 — trading 33.2% above its estimated fair value. The current OCF Margin % is 36.55%, which is near median its 10-year median of 37.81 and 267.7% above the Drug Manufacturers industry median of 9.94. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current OCF Margin % is 36.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €108.26 is trading 33.2% above its estimated GF Value™ of €81.25.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
OCF Margin %: 36.55% (near median its 10-year median of 37.81)
GF Value™: €81.25 vs. price of €108.26 (33.2% above fair value)
Industry Position: 267.7% above the Drug Manufacturers median (#37 of 959)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score
Get the complete analysis for FRA:GIS
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
